Cart
sales@molnova.com
Kisspeptin-54 (27-54) (human)
CAS No. 1135442-77-1
Kisspeptin-54 (27-54) (human)( ——— )
Catalog No. M42095 CAS No. 1135442-77-1
Kisspeptin-54 (27-54) (human) is a polypeptide that can be used for compound synthesis and pharmaceutical research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKisspeptin-54 (27-54) (human)
-
NoteResearch use only, not for human use.
-
Brief DescriptionKisspeptin-54 (27-54) (human) is a polypeptide that can be used for compound synthesis and pharmaceutical research.
-
DescriptionKisspeptin-54 (27-54) (human) is a polypeptide that can be used for compound synthesis and pharmaceutical research.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number1135442-77-1
-
Formula Weight3229.72
-
Molecular FormulaC149H226N42O39
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bevec D, et al. Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ). World Intellectual Property Organization. WO2009039984.
molnova catalog
related products
-
Catharanthine sulfat...
Catharanthine inhibits nicotinic receptor-mediated diaphragm contractions.
-
Aminooxyacetic acid ...
Aminooxyacetic acid hemihydrochloride is a malate-aspartate shuttle (MAS) inhibitor which also inhibits the GABA degradating enzyme GABA-T.
-
Euchrestaflavanone B
Euchrestaflavanone B shows antibacterial activity against Gram positive bacteria, Staphylococcus aureus, Bacillus subtilis and Bacillus cereus. Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of protein kinase CKII activity.
